Compare The Coca-Cola Co K (KO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs ResMed Inc. — how do they compare? The Coca-Cola Co K trades at $88.13 (market cap $377.63B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: The Coca-Cola Co K is far larger — about 11.8× ResMed Inc.'s market cap, and The Coca-Cola Co K pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and ResMed Inc. for 51 Days on average.
| KO | RMD | |
|---|---|---|
Market Cap | $377.63B | $31.89B |
Volume | 14,894,568 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $277.88 |
52-Week Low | $66.37 | $182.82 |
Typical Hold Time | 154 Days | 51 Days |
Enterprise Value | $404.81B | $31.24B |
Dividend Yield | 2.42% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $88.05, up 2.6% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $0.97 versus $0.92, maintaining a 61.89% gross margin and 28.56% net income margin. Recent institutional buying activity and positive analyst sentiment (60.42% buy ratings) support the stock's upward trajectory.
KO presents a compelling investment case with consistent earnings outperformance and a 64-year dividend growth streak. However, elevated valuation ratios (P/E 26.36, P/S 7.55) and regional demand divergence pose risks. The consensus price target of $95.75 suggests 8.7% upside potential from current levels, supported by strong cash flow generation and brand dominance.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
